NEW YORK, April 7, 2014 /PRNewswire/ -- Anterios, Inc., a privately held medical dermatology and aesthetic medicine biopharmaceutical company, announced today that CEO and Founder, Jon Edelson, MD will be presenting at Needham & Company's 13th Annual Healthcare Conference in New York City on April 8, 2014. Dr. Edelson will be joining a roster of presenters that include senior management representatives from approximately 120 companies in the biotechnology, specialty pharmaceutical, medical technology and diagnostic sectors are scheduled to present, including a selection of leading private companies.
"I'm looking forward to returning to Needham's Annual Healthcare Conference and sharing with the investment community the substantial progress the company has made since last year," stated Dr. Edelson. "We have now studied over 500 subjects in controlled US clinical trials of our topical botulinum product ANT-1207, which is over double the number studied at the time of last year's presentation. We've made key advances in the clinical development of ANT-1207, our leading product. As well, we recently announced the development of a next generation injectable botulinum product, AI-09, which will be complementary to ANT-1207. Anterios is proud to contribute to true innovation in medical dermatology and aesthetic medicine with the goal of addressing the unmet needs of the millions of patients who have hyperhidrosis, acne and wrinkles."
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the treatment of hyperhidrosis (excessive sweating), facial wrinkles and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.
ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office using just a gloved finger. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. botulinum, Type A.
AI-09, Botulinum Toxin Type A, For Injection, is an investigational product being developed for FDA-approved clinical indications for injectable botulinum. Unlike currently available injectable botulinum products, AI-09 will be packaged as a liquid formulation that will be ready-to-use in the physician's office without need of reconstitution. Unlike currently available injectable botulinum products, AI-09 requires no lyophilization in the manufacturing process nor does it contain albumin. As a next-generation injectable botulinum product, AI-09 offers potentially improved safety for patients as well as greater convenience and time-savings to physicians and their office staff. AI-09 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. botulinum, Type A.
About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company that is developing next generation botulinum-based prescription products for medical dermatology and aesthetic medicine. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com.
SOURCE Anterios, Inc.